A recent study has raised concerns about two widely used classes of drugs for Type 2 diabetes, sulfonylureas and basal insulin, suggesting they may be associated with a higher risk of cardiovascular events. These medications, often prescribed after metformin proves insufficient, could potentially lead to serious harm, prompting a call for a shift in treatment strategies.
Key Takeaways
- Two common Type 2 diabetes medications, sulfonylureas and basal insulin, are linked to increased cardiovascular risks.
- Patients taking these drugs are more likely to experience heart attacks, strokes, heart failure, or amputations compared to those on newer drug classes.
- The findings suggest a need for a paradigm shift in how Type 2 diabetes is treated, prioritizing newer medications with better cardiovascular profiles.
Increased Cardiovascular Risk Identified
A significant study published in JAMA Network Open has identified a potential link between sulfonylureas and basal insulin, commonly prescribed second-line treatments for Type 2 diabetes, and an elevated risk of cardiovascular events. These events can include heart attack, stroke, heart failure, and even amputation. The research indicates that patients on sulfonylureas are 36% more likely, and those on basal insulin are twice as likely, to suffer such harm compared to individuals using newer medications like DPP-4 inhibitors.
A Call for a Paradigm Shift in Treatment
Matthew O’Brien, MD, lead author of the study and assistant professor at Northwestern University Feinberg School of Medicine, emphasized the cr